Division of Gastroenterology, Hepatology and Nutrition Antiviral Efficacy/Safety Of Entecavir In Children With Hepatitis B Who Are Hbeag-positive

LIke ThisLIke ThisLIke ThisLIke ThisLIke This

Contact the Division of Gastroenterology, Hepatology and Nutrition

  • 1-617-355-6058
  • Fax: 617-730-0495
  • Schedule an Appointment:
    Monday-Friday 7:00am-8:00pm
  • Saturday 9:30am-6:00pm
  • Visit all of our locations

Principal Investigator: Maureen Jonas, MD

Department: Gastroenterology, Center for Childhood Liver Disease

Protocol Status: Open for Recruitment

Trial Description: This is a study of the use of entecavir, an oral medication, in children with chronic hepatitis B who have abnormal liver enzymes. This medication is already approved for adults with chronic hepatitis B.  This research will determine if the drug is safe and effective for children and adolescents.  This is a randomized trial, which means that some subjects will receive active drug and some will receive placebo.  After 48 weeks, if the hepatitis B has not responded, all subjects will be able to get study drug (entecavir).

Recruitment Info: The patient must be less than 18 years of age, have chronic hepatitis B and have abnormal liver enzymes.  Further details are available on request.

PI contact: Maureen Jonas, MD

PI phone: Center for Childhood Liver Disease, 617-355-5837 

Boston Children’s is so much more than a hospital—it’s a community of researchers, clinicians, administrators, support staff, innovators, teachers, patients and families, all working together to make the impossible possible. ”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital
300 Longwood Avenue, Boston, MA 02115
For Patients: 617-355-6000
For Referring Providers: 844-BCH-PEDS | 844-224-7337